Adaptive Biotechnologies is a company within the Biotechnology category. Adaptive Biotechnologies is a commercial-stage company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its proprietary immune medicine platform reveals and translates the genetic code of the immune system to develop better diagnostics and therapeutics.
Adaptive Biotechnologies was founded in 2009 and is headquartered in Seattle, WA.
Adaptive Biotechnologies is rated Leader on the Optimly Brand Authority Index, a measure of how well AI models can accurately describe the brand. The exact score is locked for unclaimed profiles.
AI narrative accuracy for Adaptive Biotechnologies is Strong. Significant factual deltas detected.
AI models classify Adaptive Biotechnologies as a Challenger. AI names competitors first.
Adaptive Biotechnologies appeared in 6 of 8 sampled buyer-intent queries (75%). Adaptive Biotechnologies dominates technical queries but is less visible in generic 'cancer monitoring' or 'liquid biopsy' searches where Natera and Guardant Health have stronger SEO footprints.
AI typically presents the company as an innovative intersection of biotech and data science. It reliably identifies their core sequencing technology but may lag on recent corporate restructuring efforts and the specific commercial status of their non-oncology pipeline. Key gap: While AI often highlights the Microsoft 'Antigen Map' partnership as a primary value driver, the company's financial reality is increasingly centered on its clinical diagnostic revenue (clonoSEQ) rather than long-term R&D partnerships.
Of 6 key facts verified about Adaptive Biotechnologies, 5 are well-documented (likely accurate across AI models), 1 have limited sourcing, and 0 are retrieval-dependent and may be inaccurate without live search.
The commercial status and availability of 'T-Detect' (their T-cell COVID test) may be misrepresented as a primary product, despite the company shifting focus away from it post-pandemic.
Buyers turn to Adaptive Biotechnologies for Standard Flow Cytometry/qPCR: Using traditional flow cytometry or specialized PCR to track disease, though with lower sensitivity than NGS., Standard Clinical Monitoring: Continuing current clinical monitoring without minimal residual disease (MRD) testing, risking missing early relapse., Specialized CRO Services: Hiring specialized labs or CROs to develop custom assays for specific clinical trials., among 3 documented problem areas.
Buyers evaluating Adaptive Biotechnologies typically ask AI models about "What is MRD testing in leukemia?", "NGS immune repertoire sequencing providers", "Best liquid biopsy for solid tumors", and 2 similar queries.
Adaptive Biotechnologies's main competitors are 10x Genomics, Guardant Health, Natera. According to AI models, these are the brands most frequently named alongside Adaptive Biotechnologies in buyer-intent queries.
Adaptive Biotechnologies's core products are clonoSEQ (MRD testing), immunoSEQ (research service), Drug Discovery (partnerships).
Adaptive Biotechnologies uses Usage-based (clinical tests) and Enterprise/Custom (drug discovery partnerships).
Adaptive Biotechnologies serves Oncologists, academic researchers, and biopharmaceutical companies.
Adaptive Biotechnologies The only company with an FDA-cleared NGS assay to detect minimal residual disease (MRD) at the sensitivity of one-in-a-million cells.
Brand Authority Index (BAI) tier: Leader (exact score locked for unclaimed brands)
Archetype: Challenger
https://optimly.ai/brand/adaptive-biotechnologies
Last analyzed: April 10, 2026
Founded: 2009
Headquarters: Seattle, WA